Stay updated on BGB324 with Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the BGB324 with Pembrolizumab in Melanoma Clinical Trial page
- Check7 days agoChange DetectedAdded Melanoma and related topic MedlinePlus Genetics as related topics on the study page.SummaryDifference0.2%

- Check14 days agoChange DetectedMelanoma and the related topic MedlinePlus Genetics were removed from the page's related topics; these changes affect metadata rather than the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check21 days agoChange DetectedMinor site revision update from v3.2.0 to v3.3.2; no changes to the study details, endpoints, or eligibility criteria were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedThe page adds Melanoma and related topics (MedlinePlus Genetics) as related topics, and removes the government funding lapse notice.SummaryDifference0.5%

- Check42 days agoChange DetectedNo significant changes detected; the study page content and layout appear unchanged.SummaryDifference0.4%

- Check49 days agoChange DetectedMelanoma and the related topic MedlinePlus Genetics were removed from the Related Topics section of the page.SummaryDifference0.2%

Stay in the know with updates to BGB324 with Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BGB324 with Pembrolizumab in Melanoma Clinical Trial page.